Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors
SANTA MONICA, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced the appointment of Richard J. Daly as a non-executive director and a member of the Audit Committee. Mr. Daly has supported the successful launch of 10 drugs during a 27-year career in the biotech and pharmaceutical industry. With his appointment, the Opiant Board now consists of six members, four of whom are independent.
“I am delighted to have Richard join our Board of Directors,” said Roger Crystal, M.D., Opiant’s Chief Executive Officer. “He has extensive biopharma experience especially around commercializing new therapies in the USA. I look forward to leveraging his vast industry expertise as we advance our addiction pipeline.”
“With the opioid crisis gripping America, and overdose deaths on the rise, more medical therapies are needed,” said Mr. Daly. “I firmly believe that Opiant has a unique opportunity to be a leader in the field of pharmacological treatments for various addictions. It strengths lie in its innovative technology platform and broad product development pipeline, which also include treatments in development for Alcohol Use Disorder and Bulimia Nervosa.”
Mr. Daly is currently the Chairman and Chief Executive Officer of Neuralstem, Inc. (Nasdaq:CUR), a clinical-stage CNS company with assets in development for the treatment of major depressive disorder, ALS, stroke, and chronic spinal cord injury. Prior to Neuralstem, he was a Managing Partner for Ravine Rock Partners, LLC, a biotech-focused management consulting firm. Previously, Mr. Daly served as President of AstraZeneca U.S. – Diabetes, a subsidiary of AstraZeneca Pharmaceutical LP. He was responsible for all functions of the $1.3 billion, 3,000 employee, primary care/specialty organization. Prior to this, Mr. Daly was co-Founder of SagePath Partners, a pharmaceutical outsourced commercial services company. Mr. Daly also held various roles of increasing responsibility over a 20-year period at Takeda Pharmaceuticals, where he was a founding member of the leadership team and most recently served as Executive Vice President, responsible for growing a $5 billion P&L and expanding the company’s commercial footprint in the Americas, and TAP Pharmaceuticals, a joint venture between Abbott Labs and Takeda that generated peak sales in excess of $3 billion.
Mr. Daly is currently a member of the Board of Directors of Catalyst Pharmaceuticals (Nasdaq:CPRX). Mr. Daly also served on the Board of Synergy Pharmaceuticals from 2015 until 2018. He earned his B.S. in Microbiology from the University of Notre Dame and his M.B.A. from the Kellogg School of Management at Northwestern University.
About Opiant Pharmaceuticals, Inc.Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. The National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Opiant’s first product, NARCAN® Nasal Spray, is exclusively licensed to Adapt Pharmaceuticals, and is approved for marketing in the U.S. and Canada. For more information please visit: www.opiant.com.
Forward-Looking StatementsThis press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
CONTACTS:Dan FerryManaging DirectorLifeSci Advisors, LLC Daniel@lifesciadvisors.com (617) 535-7746